Revolution Medicines (RVMD)
$
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
About
Business overview of Revolution Medicines (RVMD)
Revolution Medicines Inc is a clinical-stage precision oncology company focused on developing novel targeted therapies to inhibit elusive, frontier targets within notorious growth and survival pathways, with particular emphasis on the RAS and mTOR signaling pathways. The company's products includes RMC-4630, a SHP2 inhibitor, RAS(ON) portfolio, and SOS1 and 4EBP1/mTORC1 programs.
Key Insights
Critical company metrics and information
Share Price
$47.04Market Cap
$7.91 BillionTotal Outstanding Shares
168.22 Million SharesTotal Employees
490Dividend
No dividendIPO Date
February 13, 2020SIC Description
Biological Products, (no Disgnostic Substances)Homepage
https://www.revmed.com
Historical Stock Splits
Execution Date | Split Amount |
---|---|
No Historical Stock Splits |
Cash Flow Statement
October 1, 2023 to September 30, 2024
Metric | Value |
---|---|
Net Cash Flow From Operating Activities | $-539.71 Million |
Net Cash Flow From Investing Activities, Continuing | $-541.89 Million |
Net Cash Flow | $-156.64 Million |
Net Cash Flow From Operating Activities, Continuing | $-539.71 Million |
Net Cash Flow, Continuing | $-156.64 Million |
Net Cash Flow From Financing Activities | $924.96 Million |
Net Cash Flow From Investing Activities | $-541.89 Million |
Net Cash Flow From Financing Activities, Continuing | $924.96 Million |
Income Statement
October 1, 2023 to September 30, 2024
Metric | Value |
---|---|
Research and Development | $552.61 Million |
Basic Earnings Per Share | $-3.66 |
Income Tax Expense/Benefit | $343,000.00 |
Net Income/Loss Attributable To Noncontrolling Interest | $0.00 |
Net Income/Loss Attributable To Parent | $-567.06 Million |
Revenues | $742,000.00 |
Net Income/Loss Available To Common Stockholders, Basic | $-567.06 Million |
Diluted Average Shares | $341.23 Million |
Nonoperating Income/Loss | $86.48 Million |
Net Income/Loss | $-567.06 Million |
Participating Securities, Distributed And Undistributed Earnings/Loss, Basic | $0.00 |
Operating Expenses | $653.94 Million |
Basic Average Shares | $341.23 Million |
Operating Income/Loss | $-653.20 Million |
Preferred Stock Dividends And Other Adjustments | $0.00 |
Income/Loss From Continuing Operations Before Tax | $-566.72 Million |
Income/Loss From Continuing Operations After Tax | $-567.06 Million |
Other Operating Expenses | $96.33 Million |
Diluted Earnings Per Share | $-3.66 |
Balance Sheet
October 1, 2023 to September 30, 2024
Metric | Value |
---|---|
Equity Attributable To Parent | $1.57 Billion |
Intangible Assets | $56.94 Million |
Liabilities | $196.69 Million |
Noncurrent Assets | $183.86 Million |
Fixed Assets | $24.81 Million |
Noncurrent Liabilities | $85.83 Million |
Equity Attributable To Noncontrolling Interest | $0.00 |
Liabilities And Equity | $1.76 Billion |
Current Liabilities | $110.86 Million |
Accounts Payable | $24.46 Million |
Assets | $1.76 Billion |
Equity | $1.57 Billion |
Current Assets | $1.58 Billion |
Other Non-current Assets | $102.11 Million |
Other Current Liabilities | $86.41 Million |
Historical Dividends
Announcement Date | Payment Date | Record Date | Amount | Frequency |
---|---|---|---|---|
No historical dividends |
Boost your savings and earn 4.35% APY with a Marcus by Goldman Sachs savings account, a rate that's 8x the national averagewhen signing up with Financhle. No fees, no minimum deposits, backed by the financial expertise of Goldman Sachs. Terms apply.
ⓒ 2024 Financhle. All Rights Reserved.